The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The association between the GOELAMS MCL-PET prognostic index and survival in patients treated with rituximab-hypercvad (R-HyCVAD) or high-dose therapy with autologous stem cell rescue (HDT/ASCT).
T. Feldman
No relevant relationships to disclose
A. R. Mato
No relevant relationships to disclose
T. Zielonka
No relevant relationships to disclose
S. D. Rowley
No relevant relationships to disclose
S. Goldberg
No relevant relationships to disclose
M. Donato
No relevant relationships to disclose
D. S. D. Siegel
No relevant relationships to disclose
K. Facchin
No relevant relationships to disclose
A. Campaiola
No relevant relationships to disclose
D. H. Vesole
No relevant relationships to disclose
C. Bejot
No relevant relationships to disclose
S. Stives
No relevant relationships to disclose
M. Curtin
No relevant relationships to disclose
M. Miller
No relevant relationships to disclose
H. Agress
No relevant relationships to disclose
D. Panush
No relevant relationships to disclose
P. Lizotte
No relevant relationships to disclose
P. Bhattacharyya
No relevant relationships to disclose
A. Pecora
No relevant relationships to disclose
A. Goy
No relevant relationships to disclose